Which of the following is a feature of Dimenhydrinate categorized as Schedule 3?

Dimenhydrinate is classified as a Schedule 3 medication, which means it can be sold without a prescription but is not entirely unrestricted. One of the key features of Schedule 3 medications is that they are typically available for oral use. Dimenhydrinate is primarily used to prevent and treat symptoms of motion sickness and is most commonly administered in an oral form, such as tablets or liquid.

This classification allows consumers to obtain the medication more easily than stronger, prescription-only drugs, while still ensuring that there are some regulations in place regarding its sale and use. The oral route also supports a self-care approach, where individuals can manage their motion sickness symptoms without needing a healthcare professional's direct supervision for every instance.

In contrast, other options involve usage that is not aligned with the classification and common administration route of Dimenhydrinate or do not represent its status accurately within the regulatory framework. Parenteral use is generally associated with prescription medications, and topical use would pertain to formulations that are applied to the skin, which does not apply to Dimenhydrinate. The “unscheduled” option implies there would be no restrictions on sale or use, which does not apply to Dimenhydrinate, as it is categorized under Schedule 3.